Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Dec 14;47(4):895–906. doi: 10.1007/s00259-019-04601-3

Fig. 3. Relationship between disease status change, NETest category and outcome.

Fig. 3.

3A. The proportion of patients categorized as SD (NETest ≤40) or PD (NETest >40) at follow-up for each of the two groups – responders and non-responders. A PD score at time of RECIST-defined progression was evident in 80% who progressed. The disease stabilization group had SD scores in 93% with (p<0.0001).

3B. Categorization of subjects into the two NETest categories (SD/PD) was significantly associated with outcome. Those classified as SD had an mPFS that was not reached. Those categorized as PD, had a significantly lower mPFS (10 months). The Hazard Ratio (HR) (0.04) was consistent with a significant (p<0.0001) association with PRRT efficacy.